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KNOWLEDGE OF HUMAN PAPILLOMAVIRUS AND THE HUMAN 
PAPILLOMAVIRUS VACCINE IN EUROPEAN ADOLESCENTS: 
A SYSTEMATIC REVIEW 
 
ABSTRACT 
Background: The Human papillomavirus (HPV) vaccine is recommended for adolescent females 
in many European countries however there is huge variation in vaccine uptake.  
Methods: A mixed methods systematic review to ascertain the level of HPV and HPV vaccine 
knowledge that exists amongst European adolescents. Two electronic databases, Ovid Medline and 
PsychInfo, were searched from origin to September 2014.  Meta-analysis was performed for the 
two primary outcome measures (“have you heard of HPV?” and “have you heard of the HPV 
vaccine?”), assessing for the correlation between gender and knowledge. This was supplemented 
with meta-synthesis for the remaining associations and secondary outcomes.  
Results: 18 papers were included in the final review. Overall European adolescents had poor 
understanding of basic HPV and HPV vaccine knowledge. Meta-analysis identified that female 
adolescents are significantly more likely to have heard of HPV (OR 2.73, 95% CI 1.86-3.99) and 
the HPV vaccine (OR 5.64, 95% CI 2.43-13.07) compared to males. Age, higher education and a 
positive vaccination status were also associated with increased awareness. There was limited 
appreciation of more detailed HPV knowledge and uncertainty existed regarding the level of 
protection offered by the vaccine and the need for cervical screening post vaccination. 
Conclusion: The delivery of HPV education to European adolescents needs to be re-evaluated, 
since at present there appears to be significant deficiencies in their basic knowledge and 
understanding of the subject. Increasing HPV knowledge will empower adolescents to make 
informed choices regarding participation with HPV related cancer prevention health strategies.  
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INTRODUCTION 
Human papillomavirus (HPV) is the most common viral infection of the reproductive tract that 
most men and women who are sexually active will acquire at some point in their lives[1]. It is the 
main aetiological factor for cervical cancer with a prevalence of 99.7% in all cases of cervical 
cancer[2]. 
 
Following the identification of the role of HPV in the aetiology of cervical cancer, four 
prophylactic vaccines targeting various high-risk HPV types have been developed. The 
monovalent vaccine (HPV16), the bivalent vaccine (HPV 16/18), the quadrivalent vaccine (HPV 
16/18/6/11)[3] and more recently the nonavalent vaccine (HPV 16/18/6/11/31/33/45/52/58)[4]. 
The bivalent and the quadrivalent vaccines were licensed for use in 2006/2007 and even over this 
relatively short period the beneficial effects of the vaccine are already evident; with decreases in 
the incidence of high-grade cervical abnormalities, the prevalence of vaccine HPV types, and the 
incidence of genital warts[4]. 
 
The HPV vaccine is widely recommended in many European countries for female adolescents 
(aged 9-18years[5]), however independent of funding discrepancies, the uptake of the vaccine has 
been variable, ranging from <5%-86% [6-8]. Reasons for vaccine uptake are multifactorial[9,10], 
however knowledge of HPV and the HPV vaccine have been identified as key predictive factors in 
increasing uptake [11]. To date studies have shown that awareness of HPV across all populations 
is poor[12,13]. It was hoped that the health promotion campaigns, which preceded vaccine 
introduction would result in heighten awareness of HPV, thus far the evidence for this is 
lacking[14]. 
  
HPV vaccination is primarily aimed at adolescents and conveying HPV related health information 
to this group is arguably the greatest challenge for many healthcare professions[15]. In spite of 
this, it is essential that adolescents fully understand, and are able to critically appraise the 
information that they are provided, in order for them to make informed choices[16].  
 
The aim of this systematic review was to assess the level of HPV and HPV vaccine knowledge 
that exists amongst European adolescents.  
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METHODS 
A mixed methods systematic review, exploring both qualitative and quantitative data, was 
conducted to assess our aim. The two main primary outcomes that we assessed were: “have you 
heard of HPV?” and “have you heard of the HPV vaccine?”  
 
Search Strategy 
We adhered to the PRISMA (preferred reporting items for systematic reviews and meta-analyses) 
guidelines for systematic reviews[17]. Two electronic databases, Ovid Medline and PyscINFO 
were searched from establishment to September 2014. These databases were used without any 
limitations and they were deemed to be the most relevant databases for this research question. 
Searches were conducted using 11 combinations of the keywords, “HPV”, “Papillomavirus”, 
“Human papilloma virus”, “Health knowledge” “Attitudes”, “Practice”, “Patient education”, 
“Vaccine/vaccination” and “Primary prevention”. Limited to English language and human 
participants.  
 
Eligibility criteria 
All studies reporting data specifically on HPV and/or HPV vaccine knowledge in European 
adolescents were included. The upper age limit, for this review was set at a mean age of 20 years. 
This was because in some studies, which had been conducted in European secondary schools, the 
upper age limit reached 20 years[18-21]. Only studies, which were conducted in a member country 
of the European Union, were included. We excluded studies in which the main focus was vaccine 
uptake, acceptability or attitudes.  Studies providing insufficient information, for example 
letters/abstracts only, were also excluded.  
 
Critical Appraisal 
Two researchers (HP, EM) independently reviewed the full texts for quality and suitability. The 
Critical Appraisal Skills Programme (CASP) tool was used to review the qualitative studies [22] 
and a quality checklist was developed, following the principles identified by Pettigrew and 
Roberts[23] and using the Centre for Evidence-Based Management (CEBM) tool[24], for the 
quantitative survey studies.  Any discrepancies were discussed until a consensus was reached. 
 
Data Analysis 
Study features and outcomes were assembled in a tabular form, and formal meta-analysis was 
performed using RevMan [25]. A random effect model (using a Mantel–Haenszel method) was 
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used as the I2 statistic showed heterogeneity of >50%. The effect estimate was expressed as a 
pooled odds ratio (OR) with 95% confidence interval (CI) and was represented graphically by 
forest plots. Statistical heterogeneity was examined using the χ2 test and a P value of <0.05 was 
suggestive of heterogeneity. Clinical heterogeneity was examined by assessing the participants, 
intervention used, study quality and outcome measures. The meta-analysis was supplemented with 
meta-synthesis for the secondary outcome measures. 
 
RESULTS 
Study Characteristics  
The literature search revealed 905 suitable studies following the removal of duplicates 
(Supplementary file 1). The full texts of 29 articles that had met the initial inclusion criteria were 
reviewed and 11 of these studies were excluded. Reasons for exclusion included, age of 
participants, studies not assessing HPV or HPV vaccine knowledge, study assessing the effect of 
intervention and adequate information not supplied. Studies that had published results in more 
than one publication were amalgamated resulting in 4 qualitative and 14 quantitative studies to be 
included in the final review. Publication dates of the studies ranged from 2008-2013. Sample size 
ranged from 217-1769 for the quantitative and 10-87 for the qualitative studies. Most of the 
included studies had been conducted in a Western European country (UK, Italy, Sweden, 
Netherlands, Portugal, Germany), with only two from Eastern Europe, both from Hungary.    
Study characteristics are summarised in Web Tables 1 and 2 
 
Critical Appraisal  
The majority of studies were considered to be of moderate to good quality (supplementary file 2). 
The response rate was greater than 70% in all but two studies[20,26]. However many of the studies 
predominately used convenience sampling and therefore the representativeness of the data may be 
questioned.  
 
Primary Outcomes 
Awareness of HPV 
“Have you heard of HPV?” 
Twelve of the quantitative studies specifically assessed for this outcome [18-21,27-34]. Awareness 
of HPV varied significantly between the studies with the lowest level existing amongst a cohort of 
Swedish adolescents, mean age 16 years, where only 5% had ever heard of HPV [18]. The highest 
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level of awareness of HPV was noted in Italian adolescents, mean age 16 years, where 92% had 
heard of HPV [21]. Awareness of HPV in Italian female adolescents has increased over time 
[19,21,28], a similar trend has been noted for both male and female adolescents in the 
Netherlands[31,34] and Sweden[18,30].  
Factors found to be associated with greater HPV awareness included: 
1) Vaccinated girls were more likely to have heard of HPV than unvaccinated girls[35] 
(77%,n=683 vs 8.5%, n= 76; p= 0.017 [27])in two UK studies, however adolescent boys appeared 
to have an equal level of awareness as unvaccinated girls in a German study [26]. 
2) Higher education in general and in particular students studying a medical or health sciences 
related subject was found to correlate with greater awareness compared to non-health science 
subjects [31,33,34].  
3) Knowledge was found to positively increase with age [20] and in one Italian study, it was noted 
that each one year increment in age resulted in 14% increased knowledge[28]. In addition, a 
Hungarian study demonstrated that adolescents attending secondary school had better knowledge 
than those attending primary school (40%, n= 463 vs 25%, n=152; p= < 0.001) [32].  
4) Only one German study revealed a correlation with sexual experience, showing that students 
who had previous sexual experience had superior awareness of HPV than those who had never had 
sex (OR 1.53, 95% CI 1.01–2.12) [20]. 
5) Gender was found to be the greatest and most consistent predictive factor for having heard of 
HPV. Meta-analysis of eight quantitative studies showed that adolescent girls are significantly 
more likely to have heard of HPV compared to the boys, (OR 2.73, 95% CI 1.86-3.99) (Figure 1) 
[19-21,30-34]. 
 
Awareness of HPV vaccine 
“Have you heard of the HPV vaccine?” 
Five quantitative studies assessed for this outcome [18,20,21,30,32]. Highest levels of vaccine 
awareness were again found in Italian adolescents, 94.5% and 71.3% of girls and boys 
respectively, in the group who heard of HPV had also heard of the HPV vaccine [21]. This is a 
substantial improvement on the findings by Di Giuseppe et al who in 2007, found that in Italy only 
42% of those that had heard of cervical cancer, identified HPV vaccination was a preventative 
measure and only 15% knew that the vaccine was available in Italy [28]. Knowledge of the HPV 
vaccine amongst Swedish adolescents was found to be extremely low, with awareness reaching a 
maximum of 9.2% in girls in one study [30] and in another the overall awareness was only 1.1% 
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with no significant difference noted in gender [18]. Lower levels of vaccine awareness 
corresponded to low awareness of HPV in these cohorts. 
 
Meta-analysis of the four studies that analysed gender differences in awareness, found that girls 
were significantly more likely to have heard of the HPV vaccine (OR 5.64, 95% CI 2.43-13.07) 
(Figure 2)[20,21,30,32] and interestingly many adolescent boys felt that it did not even concern 
them [19].  
 
Secondary outcomes 
Mode of transmission 
On the whole adolescents had a sound understanding of the fact that HPV is a sexually transmitted 
disease [18,19,21,26-28,30-32,34,36,37]. First year medical students in a UK based study, had the 
greatest level of knowledge regarding mode of transmission[37] and the lowest levels were found 
amongst groups in which not many had heard of HPV in the first instance [18,30]. Very few 
recognised that HPV can be transmitted through genital skin-to-skin contact or non-penetrative 
intercourse [27,28,32].  Other routes of transmission, which had been erroneously suggested 
included, air-borne where students had applied the knowledge that they hold for other viruses such 
as the flu virus to HPV [38]. In addition some mentioned blood transfusions [33], the use of public 
toilets and poor intimate hygiene [21].  
 
Link to cervical cancer and genital warts 
The correlation between high-risk HPV and cervical cancer was poorly understood, with a group 
of 12-13 year old girls in the UK believing that HPV and cervical cancer were the same [38]. In 
two UK based studies, despite the majority of the participants having heard of HPV, only 50% or 
less were aware of its link to cervical cancer [27,37] and one of these studies had been conducted 
in first year medical students[37].  
Compared to boys, girls in general [20,21,30,32,34] and vaccinated girls [26] were found to have 
significantly greater knowledge of the relationship between HPV and cervical cancer. 
Misconceptions existed regarding the hereditary nature of cervical cancer, 76% of medical faculty 
students incorrectly stated hereditary cause as a risk factor [31].   
Understanding of the association between HPV and genital warts was low [18,21,27,30,32], with 
the greatest levels existing in 15-19 year old Hungarian boys [32].  
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Level of protection offered by the vaccine 
Adolescents appreciated that the HPV vaccine provided protection against cervical cancer but 
uncertainty existed on the exact level of protection offered [27,36,37]. Only a few knew that it was 
still possible to get cervical cancer after receiving the vaccine [27] and that the vaccine only offers 
protection against some of the high-risk HPV subtypes [37]. One group of girls thought that the 
vaccine would not stop them from getting cervical cancer but that it would stop them dying from it 
[36]. A minority mentioned that it may also protect against “STDs” [19] and genital warts [21]. 
Others falsely believed that the HPV vaccine also provided protection against HIV/AIDs and viral 
hepatitis [21]. The two Swedish studies revealed that adolescents felt their intention to use 
condoms would decrease after receiving the HPV vaccine and that other adolescents would feel 
the same [18,30], however Italian adolescents acknowledged the need to use condoms during 
sexual activity following vaccination [21]. 
  
Need for cervical screening in the future 
Four [27,36,38,39] UK based studies found that the need for cervical screening following 
vaccination was not clear. Some thought that cervical screening was being provided as a “back up” 
for those who were still concerned after being vaccinated rather than it being mandatory for all 
[39]. Vaccinated female medical students in the UK and Italian adolescents appeared to be more 
aware of the requirement for cervical screening [21,37].  
 
DISCUSSION 
Our review reveals that the level of HPV and HPV vaccine knowledge amongst European 
adolescents remains suboptimal. These results reinforce the findings of another review of 
European adolescents which found that of all the sexually transmitted diseases the lowest level of 
awareness existed for HPV [40]. Recent systematic reviews concluded that increased HPV 
knowledge does result in increased vaccine uptake and acceptability [11,12].  When vaccine 
recipients and their parents are provided with balanced information, they have improved 
knowledge and risk perception, which results in increased vaccine uptake[41].  
 
In this review we attempted to identify factors, which may be associated with greater HPV 
knowledge. The following factors were explored looking for any correlations. 
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Gender 
An emergent theme from our review was that female gender correlated with increased knowledge. 
Studies from across Europe showed that female adolescents had significantly more knowledge 
than males, a trend which is also replicated in the adult population [13]. This is likely to be 
reflective of the fact that HPV is primarily thought of as a women’s health problem and that the 
majority of countries presently, only recommend the HPV vaccine for females. However HPV is 
responsible for malignancies in men too, including cancers of the anus, penis, oral cavity and 
oropharynx[42] and furthermore men share an equal burden for HPV related genital warts [43]. 
Currently HPV vaccination for adolescent boys is only recommend by a few, including America, 
Canada, Australia and Austria. Furthermore, the UK's Joint Committee on Vaccination and 
Immunisation  has recently recommended that men who have sex with men (MSM) (aged 16-40 
years) should also be offered the HPV vaccine [44]. The cost effectiveness of the vaccine has been 
debated as the rational against vaccinating adolescent boys [44]. Moreover it has been argued that 
boys will receive a degree of protection from the herd immunity effect of vaccinated girls. 
However HPV vaccination is only part of the solution, abstaining from high-risk behaviour is 
equally important. Parents feel that by including boys in HPV education and in the vaccination 
campaign we can reinforce their responsibility in sexual health[45] and avoid girls feeling 
stigmatised by being the sole target [46]. The challenge will be developing educational materials, 
which are equally relevant to both genders. 
 
Introduction of the HPV vaccine into national immunisation programmes and funding 
The timing of HPV vaccine introduction across Europe has varied and integration into national 
immunisation programmes and/or funding are not universal. The results of this review do not 
consistently support the concept that the availability of a fully state funded HPV immunisation 
programme at the time of the study resulted in increased awareness. The highest levels of HPV 
awareness were noted in Italian adolescents, in a study conducted in 2009, one-two years after the 
HPV vaccine was introduced into the Italian national vaccination schedule [47] and the lowest 
levels were seen in Sweden in 2007, three years prior to implementation of the HPV vaccine [48]. 
However, studies from both Hungary [32] and the Netherlands [31,34] showed a greater level of 
HPV awareness than Germany [20], despite the former studies being conducted prior to the 
implementation of a free national HPV vaccination programme in their respective countries [5] 
and the German study taking place four years post “free of cost”  vaccine introduction in Germany 
[49]. These findings imply that much more complex factors are involved in acquiring knowledge 
and that the introduction of national HPV vaccination alone is not predictive.   
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Organisation of vaccination programme, school based versus primary care/private 
It has been proposed that countries, such as the UK and Australia, which have school based 
vaccination programmes have achieved higher vaccination coverage rates [50]. However the 
studies within our review showed that the UK, which operates a school based vaccination 
programme, has a vaccine coverage rate of 86% [7] but Portugal, where the HPV vaccine is 
administered in primary care and health centres [49], also had a comparable coverage rate of 84% 
[6]. The organization of HPV vaccine administration did not correlate with level of knowledge in 
this review, however knowledge was related to vaccine uptake: Italy, UK and Portugal had the 
highest levels of vaccine uptake and also the greatest amount of knowledge.  
 
Delivery of information 
Vaccine introduction in many European countries was preceded by health promotion campaigns, 
including school-based presentations [51,52]. The successfulness of these campaigns may be 
questioned, as overall HPV knowledge in this cohort remains insufficient. This raises the 
possibility that information may have been inappropriately targeted in some countries. McCusker 
et al, who specifically compared HPV knowledge, pre and post a HPV health promotion campaign 
in the UK, found that the campaign did not over time add much in terms of HPV knowledge [37]. 
Adolescents in this review described their main sources of information as media, schools and the 
internet [28,30,32,37]. They felt that although written information was useful, it needed to be more 
user friendly and complemented with nurse led small group discussions [38]. Currently a 
recommendation cannot be made on the most effective way of communicating HPV related 
information, as no one method has been found to be superior [50]. However it is apparent that 
adolescents are requesting more information than that which is presently available 
[28,30,32,35,36]. In addition the challenge will be maintaining knowledge over time [53]. When 
delayed post education follow-up has been conducted, even after only one month, the initially 
noted benefit is diminished [54].  Suggesting that there is a need for continued educational 
reinforcement as opposed to a single intervention session. This is particularly important with 
regards to cervical screening post vaccination.  
 
Strengths and Limitations 
There have been previous systematic reviews assessing HPV knowledge in various different 
populations [12-14,55,56] but this is the most up to date review that focuses on the primary target 
group for the HPV vaccine: adolescents.  
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Our review was a comprehensive mixed methods review, using this approach provides more 
accurate data, which is likely to have greater impact [57]. 
However it was limited by the scope of the primary studies. Five of the survey studies had not 
validated their questionnaires and there were considerable variations in the way specific accepts of 
HPV knowledge were assessed, for example prompted versus open questions.  In our review an 
upper age limit of 20 years was adopted, this meant that some of the included studies had been 
conducted at university level and although the average age did not exceed 20 years, this is a vastly 
different population. Lastly, the study populations were all heterogeneous and therefore difficult to 
truly compare.  
 
Conclusions 
Current evidence suggests that European adolescents have limited understanding of basic factual 
HPV knowledge. HPV plays a pivotal role in the present and future of preventative cancer 
strategies for both genders. Methods of delivering HPV information to this complex group need to 
be re-evaluated to promote increased awareness and empower them to make informed choices 
regarding future preventative health behaviours. 
 
 
Key Messages  
 Current evidence suggests that European adolescents lack basic factual HPV knowledge 
and that female gender is consistently associated with greater HPV awareness. 
 HPV is becoming more prevalent and is responsible for malignancies in both genders, 
however the risk of acquiring it can be reduced. 
 Previous evidence has shown that increased HPV awareness does result in increased HPV 
vaccine uptake. 
 In order to increase participation with HPV related cancer prevention health strategies, 
methods of delivering HPV related information need to be re-evaluated. 
 
Disclosures 
HP, YJ and EM have no conflict of interest. SS is in receipt of funding from North Staffordshire 
Medical Institute to explore attitudes towards cervical screening and HPV vaccination in mothers 
and daughters. 
 
 
 12 
Contributors 
HP, YJ, SS and EM were involved in planning the review and contributed equally to manuscript 
preparation and review. HP conducted the literature search and data extraction, performed the 
meta synthesis of the qualitative data and wrote the initial draft of the manuscript. YJ performed 
the statistically analysis for the meta analysis.  HP and EM contributed to quality assessment of the 
studies. All authors approved the final report. 
 
 
 
The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf 
of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide 
basis to the BMJ and co-owners or contracting owning societies (where published by the BMJ on 
their behalf), and its Licensees to permit this article (if accepted) to be published in Sexually 
Transmitted Infections and any other BMJ products and to exploit all subsidiary rights, as set out 
in our license. 
 13 
REFERENCES 
1. WHO. World Health Organisation, Human papillomavirus (HPV) and cervical cancer. 
Secondary World Health Organisation, Human papillomavirus (HPV) and cervical cancer  
2015. http://www.who.int/mediacentre/factsheets/fs380/en/. 
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of 
invasive cervical cancer worldwide. The Journal of pathology 1999;189(1):12-9 doi: 
10.1002/(sici)1096-9896(199909)189:1<12::aid-path431>3.0.co;2-f[published Online 
First: Epub Date]|. 
3. Lowndes CM. Vaccines for cervical cancer. Epidemiology and infection 2006;134(1):1-12 doi: 
10.1017/s0950268805005728[published Online First: Epub Date]|. 
4. Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and 
intraepithelial neoplasia in women. The New England journal of medicine 
2015;372(8):711-23 doi: 10.1056/NEJMoa1405044[published Online First: Epub Date]|. 
5. ECDC. European Centre for Disease Prevention and Control-Vaccine Schedule- Recommended 
immunisations for human papillomavirus infection. Secondary European Centre for 
Disease Prevention and Control-Vaccine Schedule- Recommended immunisations for 
human papillomavirus infection. http://vaccine-
schedule.ecdc.europa.eu/Pages/Scheduler.aspx. 
6. ECDC. European Centre for Disease Prevention and Control- Introduction of HPV vaccines in 
European Union countries – an update, 2012. 
7. Egland PH. Human Papillomavirus (HPV) Vaccine Coverage in England, 2008/09 to 2013/14 
A review of the full six years of the three-dose schedule, 2015. 
8. Poljak M, Seme K, Maver PJ, et al. Human Papillomavirus Prevalence and Type-Distribution, 
Cervical Cancer Screening Practices and Current Status of Vaccination Implementation in 
Central and Eastern Europe. Vaccine 2013;31, Supplement 7:H59-H70 doi: 
http://dx.doi.org/10.1016/j.vaccine.2013.03.029[published Online First: Epub Date]|. 
9. Canfell K, Egger S, Velentzis LS, et al. Factors related to vaccine uptake by young adult women 
in the catch-up phase of the National HPV Vaccination Program in Australia: Results from 
an observational study. Vaccine 2015;33(20):2387-94 doi: 
10.1016/j.vaccine.2015.01.024[published Online First: Epub Date]|. 
10. Fisher H, Trotter CL, Audrey S, MacDonald-Wallis K, Hickman M. Inequalities in the uptake 
of human papillomavirus vaccination: a systematic review and meta-analysis. International 
journal of epidemiology 2013;42(3):896-908 doi: 10.1093/ije/dyt049[published Online 
First: Epub Date]|. 
11. Kessels SJ, Marshall HS, Watson M, Braunack-Mayer AJ, Reuzel R, Tooher RL. Factors 
associated with HPV vaccine uptake in teenage girls: a systematic review. Vaccine 
 14 
2012;30(24):3546-56 doi: 10.1016/j.vaccine.2012.03.063[published Online First: Epub 
Date]|. 
12. Chan ZCY, Chan TS, Ng KK, Wong ML. A Systematic Review of Literature about Women's 
Knowledge and Attitudes toward Human Papillomavirus (HPV) Vaccination. Public 
Health Nursing 2012;29(6):481-89 doi: 10.1111/j.1525-1446.2012.01022.x[published 
Online First: Epub Date]|. 
13. Klug SJ, Hukelmann M, Blettner M. Knowledge about infection with human papillomavirus: a 
systematic review. Preventive medicine 2008;46(2):87-98 doi: 
10.1016/j.ypmed.2007.09.003[published Online First: Epub Date]|. 
14. Hendry M, Lewis R, Clements A, Damery S, Wilkinson C. "HPV? Never heard of it!": a 
systematic review of girls' and parents' information needs, views and preferences about 
human papillomavirus vaccination. Vaccine 2013;31(45):5152-67 doi: 
10.1016/j.vaccine.2013.08.091[published Online First: Epub Date]|. 
15. Brown EC, Little P, Leydon GM. Communication challenges of HPV vaccination. Family 
practice 2010;27(2):224-9 doi: 10.1093/fampra/cmp087[published Online First: Epub 
Date]|. 
16. GMC. General Medical Council-"Consent: patients and doctors making decisions together", 
2008. 
17. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses: The PRISMA StatementThe PRISMA Statement. Annals of 
Internal Medicine 2009;151(4):264-69 doi: 10.7326/0003-4819-151-4-200908180-
00135[published Online First: Epub Date]|. 
18. Hoglund AT, Tyden T, Hannerfors AK, Larsson M. Knowledge of human papillomavirus and 
attitudes to vaccination among Swedish high school students. International journal of STD 
& AIDS 2009;20(2):102-7 doi: 10.1258/ijsa.2008.008200[published Online First: Epub 
Date]|. 
19. Pelucchi C, Esposito S, Galeone C, et al. Knowledge of human papillomavirus infection and 
its prevention among adolescents and parents in the greater Milan area, Northern Italy. 
BMC public health 2010;10:378 doi: 10.1186/1471-2458-10-378[published Online First: 
Epub Date]|. 
20. Samkange-Zeeb F, Mikolajczyk RT, Zeeb H. Awareness and knowledge of sexually 
transmitted diseases among secondary school students in two German cities. Journal of 
community health 2013;38(2):293-300 doi: 10.1007/s10900-012-9614-4[published Online 
First: Epub Date]|. 
21. Sopracordevole F, Cigolot F, Gardonio V, Di Giuseppe J, Boselli F, Ciavattini A. Teenagers' 
knowledge about HPV infection and HPV vaccination in the first year of the public 
vaccination programme. European journal of clinical microbiology & infectious diseases : 
 15 
official publication of the European Society of Clinical Microbiology 2012;31(9):2319-25 
doi: 10.1007/s10096-012-1571-4[published Online First: Epub Date]|. 
22. CASP. CRITICAL APPRAISAL SKILLS PROGRAMME - 10 questions to help you make 
sense of qualitative research. Secondary CRITICAL APPRAISAL SKILLS 
PROGRAMME - 10 questions to help you make sense of qualitative research  2011. 
http://www.casp-uk.net/#!casp-tools-checklists/c18f8. 
23. Mark Petticrew, Roberts H. Systematic Reviews in the Social Sciences: a Practical Guide.: 
Blackwell: Oxford, 2006. 
24. (CEBMa) CfE-BM. Critical Appraisal of a Survey. Secondary Critical Appraisal of a Survey. 
http://www.cebma.org/wp-content/uploads/Critical-Appraisal-Questions-for-a-Survey.pdf. 
25. Review Manager 5.3. The Cochrane Collaboration. Copenhagen: The Nordic Cochrane Centre; 
2014 [program].  
 
 
26. Stocker P, Dehnert M, Schuster M, Wichmann O, Delere Y. Human papillomavirus vaccine 
uptake, knowledge and attitude among 10th grade students in Berlin, Germany, 2010. 
Human vaccines & immunotherapeutics 2013;9(1):74-82 doi: 10.4161/hv.22192[published 
Online First: Epub Date]|. 
27. Bowyer HL, Marlow LA, Hibbitts S, Pollock KG, Waller J. Knowledge and awareness of HPV 
and the HPV vaccine among young women in the first routinely vaccinated cohort in 
England. Vaccine 2013;31(7):1051-6 doi: 10.1016/j.vaccine.2012.12.038[published Online 
First: Epub Date]|. 
28. Di Giuseppe G, Abbate R, Liguori G, Albano L, Angelillo IF. Human papillomavirus and 
vaccination: knowledge, attitudes, and behavioural intention in adolescents and young 
women in Italy. British journal of cancer 2008;99(2):225-9 doi: 
10.1038/sj.bjc.6604454[published Online First: Epub Date]|. 
29. Forster AS, Marlow LA, Wardle J, Stephenson J, Waller J. Interest in having HPV vaccination 
among adolescent boys in England. Vaccine 2012;30(30):4505-10 doi: 
10.1016/j.vaccine.2012.04.066[published Online First: Epub Date]|. 
30. Gottvall M, Larsson M, Hoglund AT, Tyden T. High HPV vaccine acceptance despite low 
awareness among Swedish upper secondary school students. The European journal of 
contraception & reproductive health care : the official journal of the European Society of 
Contraception 2009;14(6):399-405 doi: 10.3109/13625180903229605[published Online 
First: Epub Date]|. 
31. Lenselink CH, Schmeink CE, Melchers WJ, et al. Young adults and acceptance of the human 
papillomavirus vaccine. Public health 2008;122(12):1295-301 doi: 
10.1016/j.puhe.2008.02.010[published Online First: Epub Date]|. 
 16 
32. Marek E, Dergez T, Rebek-Nagy G, et al. Adolescents' awareness of HPV infections and 
attitudes towards HPV vaccination 3 years following the introduction of the HPV vaccine 
in Hungary. Vaccine 2011;29(47):8591-8 doi: 10.1016/j.vaccine.2011.09.018[published 
Online First: Epub Date]|. 
33. Medeiros R, Ramada D. Knowledge differences between male and female university students 
about human papillomavirus (HPV) and cervical cancer: Implications for health strategies 
and vaccination. Vaccine 2010;29(2):153-60 doi: 10.1016/j.vaccine.2010.10.068[published 
Online First: Epub Date]|. 
34. Schmeink CE, Gosens KC, Melchers WJ, Massuger LF, Bekkers RL. Young adults awareness 
of HPV and vaccine acceptance after introduction of the HPV vaccine in the Dutch 
national vaccination program. European journal of gynaecological oncology 
2011;32(5):481-6  
35. Williams K, Forster A, Marlow L, Waller J. Attitudes towards human papillomavirus 
vaccination: a qualitative study of vaccinated and unvaccinated girls aged 17-18 years. The 
journal of family planning and reproductive health care / Faculty of Family Planning & 
Reproductive Health Care, Royal College of Obstetricians & Gynaecologists 
2011;37(1):22-5 doi: 10.1136/jfprhc.2010.0017[published Online First: Epub Date]|. 
36. Hilton S, Smith E. "I thought cancer was one of those random things. I didn't know cancer 
could be caught...": adolescent girls' understandings and experiences of the HPV 
programme in the UK. Vaccine 2011;29(26):4409-15 doi: 
10.1016/j.vaccine.2011.03.101[published Online First: Epub Date]|. 
37. McCusker SM, Macqueen I, Lough G, Macdonald AI, Campbell C, Graham SV. Gaps in 
detailed knowledge of human papillomavirus (HPV) and the HPV vaccine among medical 
students in Scotland. BMC public health 2013;13:264 doi: 10.1186/1471-2458-13-
264[published Online First: Epub Date]|. 
38. Racktoo S, Coverdale G. ‘HPV? Never heard of it’ Students and the HPV vaccine. British 
Journal of School Nursing 2009;4(7):328-34 doi: 
doi:10.12968/bjsn.2009.4.7.44110[published Online First: Epub Date]|. 
39. Henderson L, Clements A, Damery S, Wilkinson C, Austoker J, Wilson S. 'A false sense of 
security'? Understanding the role of the HPV vaccine on future cervical screening 
behaviour: a qualitative study of UK parents and girls of vaccination age. Journal of 
medical screening 2011;18(1):41-5 doi: 10.1258/jms.2011.010148[published Online First: 
Epub Date]|. 
40. Samkange-Zeeb FN, Spallek L, Zeeb H. Awareness and knowledge of sexually transmitted 
diseases (STDs) among school-going adolescents in Europe: a systematic review of 
published literature. BMC public health 2011;11:727 doi: 10.1186/1471-2458-11-
727[published Online First: Epub Date]|. 
 17 
41. Wegwarth O, Kurzenhauser-Carstens S, Gigerenzer G. Overcoming the knowledge-behavior 
gap: The effect of evidence-based HPV vaccination leaflets on understanding, intention, 
and actual vaccination decision. Vaccine 2014;32(12):1388-93 doi: 
10.1016/j.vaccine.2013.12.038[published Online First: Epub Date]|. 
42. Dillner J. Prevention of Human Papillomavirus-Associated Cancers. Seminars in oncology 
2015;42(2):272-83 doi: 10.1053/j.seminoncol.2014.12.028[published Online First: Epub 
Date]|. 
43. Stanley M. Perspective: Vaccinate boys too. Nature 2012;488(7413):S10-S10  
44. Kirby T. UK committee recommends HPV vaccination for MSM. The Lancet. Oncology 
2015;16(1):e7 doi: 10.1016/s1470-2045(14)71128-3[published Online First: Epub Date]|. 
45. Noakes K, Yarwood J, Salisbury D. Parental response to the introduction of a vaccine against 
human papilloma virus. Human vaccines 2006;2(6):243-8  
46. Katz ML, Reiter PL, Heaner S, Ruffin MT, Post DM, Paskett ED. Acceptance of the HPV 
vaccine among women, parents, community leaders, and healthcare providers in Ohio 
Appalachia. Vaccine 2009;27(30):3945-52 doi: 10.1016/j.vaccine.2009.04.040[published 
Online First: Epub Date]|. 
47. King LA, Levy-Bruhl D, O'Flanagan D, et al. Introduction of human papillomavirus (HPV) 
vaccination into national immunisation schedules in Europe: Results of the VENICE 2007 
survey. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European 
communicable disease bulletin 2008;13(33)  
48. Tegnell A, Dillner J, Andrae B. Introduction of human papillomavirus (HPV) vaccination in 
Sweden. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European 
communicable disease bulletin 2009;14(6)  
49. Markowitz LE, Tsu V, Deeks SL, et al. Human papillomavirus vaccine introduction--the first 
five years. Vaccine 2012;30 Suppl 5:F139-48 doi: 
10.1016/j.vaccine.2012.05.039[published Online First: Epub Date]|. 
50. Fu LY, Bonhomme LA, Cooper SC, Joseph JG, Zimet GD. Educational interventions to 
increase HPV vaccination acceptance: a systematic review. Vaccine 2014;32(17):1901-20 
doi: 10.1016/j.vaccine.2014.01.091[published Online First: Epub Date]|. 
51. Steckelberg A, Albrecht M, Kezle A, Kasper J, Muhlhauser I. Impact of numerical information 
on risk knowledge regarding human papillomavirus (HPV) vaccination among schoolgirls: 
a randomised controlled trial. German medical science : GMS e-journal 2013;11:Doc15 
doi: 10.3205/000183[published Online First: Epub Date]|. 
52. Chadenier GM, Colzani E, Faccini M, Borriello CR, Bonazzi C. Assessment of the first HPV 
vaccination campaign in two northern Italian health districts. Vaccine 2011;29(26):4405-8 
doi: 10.1016/j.vaccine.2011.04.007[published Online First: Epub Date]|. 
 18 
53. Brabin L, Stretch R, Roberts SA, Elton P, Baxter D, McCann R. Survey of girls' recall of a 
film providing information on human papillomavirus and cervical cancer 6 months after an 
offer of vaccination. Vaccine 2010;28(25):4210-4 doi: 
10.1016/j.vaccine.2010.03.077[published Online First: Epub Date]|. 
54. Doherty K, Low KG. The Effects of a Web-Based Intervention on College Students' 
Knowledge of Human Papillomavirus and Attitudes toward Vaccination. International 
Journal of Sexual Health 2008;20(4):223-32 doi: 10.1080/19317610802411177[published 
Online First: Epub Date]|. 
55. Marlow LAV. HPV vaccination among ethnic minorities in the UK: knowledge, acceptability 
and attitudes. British journal of cancer 2011;105(4):486-92  
56. Mishra A. Implementing HPV vaccines: public knowledge, attitudes, and the need for 
education. International quarterly of community health education 2010;31(1):71-98 doi: 
10.2190/IQ.31.1.f[published Online First: Epub Date]|. 
57. Harden A. Mixed-Methods Systematic Reviews: Integrating Quantitative and Qualitative 
Findings. Focus: A Publica- tion of the National Center for the Dissemination of Disability 
Research (NCDDR) Technical Brief. Secondary Mixed-Methods Systematic Reviews: 
Integrating Quantitative and Qualitative Findings. Focus: A Publica- tion of the National 
Center for the Dissemination of Disability Research (NCDDR) Technical Brief  2010. 
http://www.ktdrr.org/ktlibrary/articles_pubs/ncddrwork/focus/focus25/Focus25.pdf. 
 
 
 
 
 
Figure 1 – Meta-analysis results for the outcome” Have you heard of HPV?” A comparison 
between genders 
Figure 2 - Meta-analysis results for the outcome” Have you heard of the HPV vaccine?” A 
comparison between genders 
Web Table 1- Study Characteristics of qualitative studies 
Web Table 2- Study characteristics for survey studies 
